Merck
Expertise Partner
Merck, a leading science and technology company, unites Millipore® and SAFC® products and services to address bio/pharmaceutical challenges and deliver new options for traditional and novel modalities, including process intensification and digital transformation. Our options become your opportunities, empowering you to design a roadmap for efficient and scalable bio/pharmaceutical processes.
TriLink BioTechnologies
Expertise Partner
TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organization (CDMO) for the synthesis of nucleic acids, NTPs and mRNA capping analogs. TriLink has scale-up expertise and unique mRNA, oligonucleotide & plasmid production capabilities for companies focused on therapeutic, vaccine, diagnostic and biopharmaceutical breakthroughs. Biopharma companies turn to TriLink as a critical supplier of modified nucleic acids and as a CDMO partner to help them move from early research into clinical trials.
Hongene Bio
Expertise Partner
Established in 1998, Hongene Biotech has been specialized in the production of nucleic acid raw materials for more than 25 years, covering nucleosides and modified nucleosides, nucleotides, phosphonamidites, GalNAc delivery molecules and enzymes. The annual capacity of phosphonamidites is 58 tons and nucleoside triphosphates is 54,000 liters (equivalent of 1.05 billion doses of mRNA vaccines). To date, Hongene has over 1,600 employees globally with over 400 R&D staff. Hongene brand is highly recognized by major pharmaceutical companies and biotech companies developing mRNA and oligonucleotide drugs. Hongene's products have entered almost all nucleic acid drug pipelines worldwide. During the Covid19 pandemic, Hongene was the largest supplier of raw materials used in billions of mRNA COVID-19 vaccines. Currently, the company has established end-to-end mRNA CDMO capability, provide one stop shopping from raw materials to final product, supporting clients from preclinical research to commercialization.
Sartorius
Hosting Partner
Sartorius BIA Separations develops and manufactures market leading CIM® monolithic chromatographic columns for purification and analysis of large biomolecules, such as viruses, plasmids, and mRNA, which are applied in cell and gene therapies. Sartorius BIA’s Cornerstone® Biomanufacturing Development Services are result of more than 20 years of hands-on experience with the most challenging biopharmaceutical products and offer a comprehensive approach of integrated process development solutions and novel technology designed to improve the robustness and yield of large biomolecules production, while improving the safety of therapeutic products. Sartorius BIA’s technology for manufacturing-scale purification is already used in production of the first commercialised advanced therapeutics.
Sartorius BIA Separations also has a keen presence with novel drug candidates in the clinical pipeline.
MediciBio
Innovation Partner
MediciBio is a biotechnology company pioneering next-generation LNP platforms and innovative genetic therapeutics. Our proprietary LNP technology integrates versatility, safety, and precision, supporting a wide range of administration routes and therapeutic modalities. The platform drives the development of mRNA-based vaccines, therapeutics, and antibodies, as well as in vivo CAR therapies, and continues to advance through the growth of our internal pipeline and strategic global collaborations, including licensing agreements with partners worldwide.
FUJIFILM
Innovation Partner
FUJIFILM Toyama Chemical (FFTC), one of the core companies in the Fujifilm Group's healthcare segment, is committed to solving social issues through its pharmaceutical business. Leveraging over 40 years of expertise in anti-infective drugs, FFTC focuses on contract manufacturing as it is the only company capable of manufacturing sterile penicillin antibiotic products in Japan.
In addition, FFTC has launched CDMO services for mRNA, LNPs, liposomes, and ADCs. FFTC provide end-to-end CDMO services leveraging our unique technology platforms and a state-of-the-art facility. Moving forward, FFTC will expand the CDMO business to meet customer needs.
Hanmi Fine Chemical
Innovation Partner
Hanmi Fine Chemical has been actively expanding into the mRNA materials space as part of its high tech CDMO business. Hanmi Fine Chemical’s representative product HanmiCap® promises cost effective and efficient mRNA R&D. Hanmi Fine Chemical also offers contract manufacturing services for customized lipids and polymers used for nanoparticles.
4basebio
Innovation Partner
4basebio is a Cambridge-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid based systems. The company offers application specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. These solutions help partners accelerate proof-of-concept studies and reach clinical milestones more efficiently, while maintaining the highest standards of safety and quality. With a focus on innovation, flexibility, and precision, 4basebio equips biopharma and academic partners with the tools to unlock the full potential of genetic medicine.